Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer’s Disease

Details

Publisher
Sage Publications
Copyright
© 2012 by SAGE Publications
ISSN
1533-3175
eISSN
1938-2731
D.O.I.
10.1177/1533317512454708
Publisher site
See Article on Publisher Site

Preview Only

Expand Tray Hide Tray

Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer’s Disease

Abstract

To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg/d versus 10 mg/d for moderate-to-severe Alzheimer’s disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world (RoW)) patient subgroups. In both subgroups, donepezil 23 mg/d was associated with significantly greater cognitive benefits than donepezil 10 mg/d. Significant global function benefits of donepezil 23 mg/d over 10 mg/d were also observed in the US subgroup only. Compared with RoW patients, US patients had relatively more severe AD, had been treated with donepezil 10 mg/d for longer periods prior to the start of the study, and a higher proportion took concomitant memantine. In both subgroups, donepezil had acceptable tolerability; overall incidence of treatment-emergent adverse events was higher in patients receiving donepezil 23 mg/d compared with donepezil 10 mg/d.
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/sage/subgroup-analysis-of-us-and-non-us-patients-in-a-global-study-of-high-4FlWnAbPc2